Dubai, UAE – The Emirates Pharmaceutical Corporation announced the activation of a new mechanism, which aims to break the monopoly of medical products, and requires pharmaceutical companies to appoint more than one agent for each medical product traded in the Emirates, in a precedent that is the first of its kind.
This decision comes within the framework of implementing the provisions of Federal Decree-Law No. (38) of 2024 regarding medical products, the pharmacy profession, and pharmaceutical facilities.
In line with the UAE’s efforts to enhance national readiness for pharmaceutical security and ensure the sustainable availability of medical products in the country.
The decision also increases the attractiveness of the business environment for investment, enhancing the country’s global competitiveness and expanding the treatment options available for the same disease.
The new mechanism aims to end the monopoly on medical products for the first time and reduce the risk of supply disruptions in emergencies or operational challenges.
To ensure the sustainable availability of medical products and meet the needs of patients and health facilities at all times.
The mechanism enhances the resilience of supply chains by accelerating responses to demand changes and health crises, and increases distribution efficiency by improving inventory management.
In addition to accelerating the efficient arrival of medical products to various emirates of the country, diversifying distribution channels, and preventing monopolistic practices that would control the quantities or timing of supply.
In addition to stimulating fair competition in logistics services, and raising standards of quality, warehousing and logistics services.
